BHC Strangle Strategy
BHC (Bausch Health Companies Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NYSE.
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally.
BHC (Bausch Health Companies Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $1.98B, a beta of 0.42 versus the broader market, a 52-week range of 4.41-8.69, average daily share volume of 2.0M, a public-listing history dating back to 1994, approximately 21K full-time employees. These structural characteristics shape how BHC stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.42 indicates BHC has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on BHC?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current BHC snapshot
As of May 15, 2026, spot at $5.42, ATM IV 52.99%, IV rank 10.54%, expected move 15.19%. The strangle on BHC below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this strangle structure on BHC specifically: BHC IV at 52.99% is on the cheap side of its 1-year range, which favors premium-buying structures like a BHC strangle, with a market-implied 1-standard-deviation move of approximately 15.19% (roughly $0.82 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated BHC expiries trade a higher absolute premium for lower per-day decay. Position sizing on BHC should anchor to the underlying notional of $5.42 per share and to the trader's directional view on BHC stock.
BHC strangle setup
The BHC strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With BHC near $5.42, the first option leg uses a $5.69 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed BHC chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 BHC shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $5.69 | N/A |
| Buy 1 | Put | $5.15 | N/A |
BHC strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
BHC strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on BHC. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on BHC
Strangles on BHC are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BHC chain.
BHC thesis for this strangle
The market-implied 1-standard-deviation range for BHC extends from approximately $4.60 on the downside to $6.24 on the upside. A BHC long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current BHC IV rank near 10.54% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on BHC at 52.99%. As a Healthcare name, BHC options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to BHC-specific events.
BHC strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. BHC positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move BHC alongside the broader basket even when BHC-specific fundamentals are unchanged. Always rebuild the position from current BHC chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on BHC?
- A strangle on BHC is the strangle strategy applied to BHC (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With BHC stock trading near $5.42, the strikes shown on this page are snapped to the nearest listed BHC chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are BHC strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the BHC strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 52.99%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a BHC strangle?
- The breakeven for the BHC strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current BHC market-implied 1-standard-deviation expected move is approximately 15.19%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on BHC?
- Strangles on BHC are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the BHC chain.
- How does current BHC implied volatility affect this strangle?
- BHC ATM IV is at 52.99% with IV rank near 10.54%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.